About Me
Dr. Reza Mehrazin is Professor and board certified American urologist at Icahn School of Medicine at Mount Sinai. Dr. Mehrazin joined the surgical staff at Mount Sinai School of Medicine after completing a two-year Society of Urologic Oncology (SUO) accredited fellowship at a highly prestigious National Cancer Institute (NCI) designated cancer center, Fox Chase Cancer Center. Prior to his fellowship, he completed his general surgery internship and urology residency at University of Tennessee Health Science Center.
Dr. Mehrazin’s clinical expertise is in open, laparoscopic, and robotic surgical techniques for the treatment of various urologic cancers, which allows him to tailor a specific treatment plan based on individual patient need and preferences. He is one of the few urologists in the region who has extensive training and certified in performing minimally invasive organ preserving and reconstructive techniques to preserve function and quality of life for patients with kidney cancer and bladder cancer. He performs both robotic (using da Vinci® technology) and open cystectomies with continent urinary diversion (new bladder), nephron-sparing (kidney preserving) partial nephrectomy, nerve-sparing prostatectomy, partial or total adrenalectomy, retroperitoneal lymph node dissection for testicular cancer, and endoscopic nephron-sparing management of patients with upper tract urothelial carcinomas. He also has a special clinical interest in the management of patients with metastatic and advanced kidney cancer with tumors extending into the surrounding organs or major vessels, as well as salvage bladder surgeries following radiation therapy.
His research interests revolve around novel clinical and surgical treatment of kidney and bladder cancer. Over 350 of his abstracts have been presented at international, national, and regional scientific meetings. He has authored and co-authored over 170 scientific papers which are published or currently in press in major, high impact journals.
In addition, he has authored several textbook chapters on robotic surgical techniques, kidney tumors, bladder cancer, prostate cancer, upper tract urothelial carcinoma, and adrenal tumors. He is a member of editorial board for several medical journals and Practice Guidelines Committees of the American Urological Association. He is also the Director of Society of Urologic Oncology fellowship program at Mount Sinai Hospital.
He is a member of the American Urological Association, American College of Surgeons, Society of Urologic Oncology and American Society of Clinical Oncology.
He takes a multi-disciplinary approach and works closely with Medical Oncology and Radiation Oncology physicians at Mount Sinai Health Care System to deliver comprehensive care and support for each patient.
Dr. Mehrazin's Patients Stories:
Mets' Baseball Team voice Howie Rose, reveals bladder cancer battle
NewYork Post:
Member of New York Police Department with Kidney Cancer:
https://www.mountsinai.org/about/patient-stories/finding-the-best-doctor-through-a-best-friend
BLADDER CANCER
Dr. Mehrazin speaks about Robotic Cystectomy http://blog.mountsinai.org/blog/robotic-cystectomy-vs-open-cystectomy/
KIDNEY CANCER or Renal Cell Carcinoma:
NY Daily News:
Dr. Mehrazin discusses kidney cancer signs and symptoms of new advances in treatment http://www.nydailynews.com/life-style/daily-checkup-kidney-cancer-attention-article-1.2385577
Dr. Mehrazin comments discusses his research about close monitoring of renal tumors https://www.mountsinai.org/about/newsroom/2015/close-monitoring-of-renal-tumors-may-provide-alternative-to-surgery
Language
Position
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Morningside
- Mount Sinai Queens
- The Mount Sinai Hospital
- New York Eye and Ear Infirmary of Mount Sinai
- Mount Sinai West
Research Topics
Anti-Tumor Therapy, Cancer, Imaging, Kidney, Patient Care, Patient Centered Outcomes Research, Prostate, Robotic Surgery, Technology & Innovation
About Me
Dr. Reza Mehrazin is Professor and board certified American urologist at Icahn School of Medicine at Mount Sinai. Dr. Mehrazin joined the surgical staff at Mount Sinai School of Medicine after completing a two-year Society of Urologic Oncology (SUO) accredited fellowship at a highly prestigious National Cancer Institute (NCI) designated cancer center, Fox Chase Cancer Center. Prior to his fellowship, he completed his general surgery internship and urology residency at University of Tennessee Health Science Center.
Dr. Mehrazin’s clinical expertise is in open, laparoscopic, and robotic surgical techniques for the treatment of various urologic cancers, which allows him to tailor a specific treatment plan based on individual patient need and preferences. He is one of the few urologists in the region who has extensive training and certified in performing minimally invasive organ preserving and reconstructive techniques to preserve function and quality of life for patients with kidney cancer and bladder cancer. He performs both robotic (using da Vinci® technology) and open cystectomies with continent urinary diversion (new bladder), nephron-sparing (kidney preserving) partial nephrectomy, nerve-sparing prostatectomy, partial or total adrenalectomy, retroperitoneal lymph node dissection for testicular cancer, and endoscopic nephron-sparing management of patients with upper tract urothelial carcinomas. He also has a special clinical interest in the management of patients with metastatic and advanced kidney cancer with tumors extending into the surrounding organs or major vessels, as well as salvage bladder surgeries following radiation therapy.
His research interests revolve around novel clinical and surgical treatment of kidney and bladder cancer. Over 350 of his abstracts have been presented at international, national, and regional scientific meetings. He has authored and co-authored over 170 scientific papers which are published or currently in press in major, high impact journals.
In addition, he has authored several textbook chapters on robotic surgical techniques, kidney tumors, bladder cancer, prostate cancer, upper tract urothelial carcinoma, and adrenal tumors. He is a member of editorial board for several medical journals and Practice Guidelines Committees of the American Urological Association. He is also the Director of Society of Urologic Oncology fellowship program at Mount Sinai Hospital.
He is a member of the American Urological Association, American College of Surgeons, Society of Urologic Oncology and American Society of Clinical Oncology.
He takes a multi-disciplinary approach and works closely with Medical Oncology and Radiation Oncology physicians at Mount Sinai Health Care System to deliver comprehensive care and support for each patient.
Dr. Mehrazin's Patients Stories:
Mets' Baseball Team voice Howie Rose, reveals bladder cancer battle
NewYork Post:
Member of New York Police Department with Kidney Cancer:
https://www.mountsinai.org/about/patient-stories/finding-the-best-doctor-through-a-best-friend
BLADDER CANCER
Dr. Mehrazin speaks about Robotic Cystectomy http://blog.mountsinai.org/blog/robotic-cystectomy-vs-open-cystectomy/
KIDNEY CANCER or Renal Cell Carcinoma:
NY Daily News:
Dr. Mehrazin discusses kidney cancer signs and symptoms of new advances in treatment http://www.nydailynews.com/life-style/daily-checkup-kidney-cancer-attention-article-1.2385577
Dr. Mehrazin comments discusses his research about close monitoring of renal tumors https://www.mountsinai.org/about/newsroom/2015/close-monitoring-of-renal-tumors-may-provide-alternative-to-surgery
Language
Position
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Morningside
- Mount Sinai Queens
- The Mount Sinai Hospital
- New York Eye and Ear Infirmary of Mount Sinai
- Mount Sinai West
Research Topics
Anti-Tumor Therapy, Cancer, Imaging, Kidney, Patient Care, Patient Centered Outcomes Research, Prostate, Robotic Surgery, Technology & Innovation
Clinical Focus
- Adrenal Cortical Carcinoma
- Adrenal Gland Tumors
- Adrenalectomy
- Adrenocortical Carcinoma
- Bladder Cancer
- Cystectomy
- Cystoscopy
- Evaluation of Kidney Mass
- Kidney Cancer
Show More
Education
MD, Medical University of the Americas-Nevis
Internship, Surgery (General Surgery)
UT/Methodist Healthcare Radiology Residency
Residency, Urology
UT/Methodist Healthcare Radiology Residency
Fellowship, Urologic Oncology
Fox Chase Cancer Center
Certifications
American Board of Urology
Awards
2023
American Urological Association Leadership Program
2017
Resident Teaching Award
Mount Sinai School of Medicine Department of Urology
Castle Connolly Top Doctors
Super Doctors
New York Rising Stars
Research
· Dr. Mehrazin has clinical and laboratory research interests in identifying biomarkers, anticancer agents and cutting-edge technologies to improve long-term surgical and functional outcomes in patients with various urologic cancers.
“I understand the emotional burden that diagnosis of cancer can have on the patient and family members. I always would treat my patients as I would treatment my own family and friends. I understand quality of life is superbly important and would personalize treatment for each patient through extensive discussions and effective communication.”
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
Patients with Cigna Medicare Advantage or Humana Medicare Advantage insurance: Please read this important message before booking to find out if out-of-network costs may apply to your next visit.
- 5 East 98th Street5 East 98th Street, 6th Floor, New York, NY, 10029
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Patient Experience Star Ratings and Comments
The Patient Experience Star Rating reflects our patients’ perception of how well their Mount Sinai provider communicated with them during an office visit. The Star Rating is based on patient responses to three questions on a patient experience survey, a standardized questionnaire sent to verified patients and distributed by a third party vendor, Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Care Provider’s Explanation
Care Provider’s Concern
Likelihood to Recommend Care Provider
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Mehrazin during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Intuitive Surgical, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Mehrazin during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Intuitive Surgical, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.